• Clinical Insights: January 31, 2019

    Welcome to RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more.   New Drug Approval Tosymra™ (sumatriptan) – New Drug Approval – January 28, 2019 – Dr. Reddy’s Laboratories Ltd. and its subsidiary, Promius Pharma, LLC announced the approval of… Read more »

  • Contract Pharmacy Solutions at 340B Winter Conference

    RxStrategies emphasizes a conservative approach to 340B contract pharmacy administration to maintain program compliance. Our simple, all-inclusive fee ensures more of the 340B savings remain with the Covered Entity. In addition, our audit-proven eligibility matching algorithm drives matches to qualify each individual transaction. Our Split Billing platform simplifies the process of mixed-use inventory virtualization and… Read more »

  • Clinical Insights – December 27, 2018

    Welcome to the December 27, 2018 edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. New Drug Approval  Ultomiris™ (ravulizumab)– New Drug Approval – December 21, 2018 – The U.S. Food and Drug Administration approved Ultomiris™ (ravulizumab) injection for the treatment of adult patients with paroxysmal… Read more »

  • 340B Insider – December 2018

    Welcome to the December edition of RxStrategies’ 340B Insider, a concise communication to provide a quick highlight of updates from RxStrategies’ view. Visit our website to read more.   340B INDUSTRY NEWS Read below for recent news from 340B Health. THE U.S. HOUSE PASSES BILL TO KEEP DRUG COMPANIES FROM OVERCHARGING MEDICAID The bipartisan bill, from… Read more »

  • Ensure Effective 340B Management in 2019

    As we near the New Year, health systems nationwide are seeking the most effective processes and services for enterprise 340B program management. Ensure compliance and efficiency in 2019 with RxStrategies, the clear choice for innovative software, high-touch service, unwavering program compliance and maximum 340B savings. Our robust retail and specialty pharmacy networks deliver high capture… Read more »

  • 340B Insider – November 2018

                  Welcome to the November 2018 edition of RxStrategies’ 340B Insider, a concise communication to provide a quick highlight of updates from RxStrategies’ view.   340B INDUSTRY NEWS Read below for recent news from 340B Health. MEDICARE 340B CUTS WILL CONTINUE AND EXPAND IN 2019 Medicare cuts of nearly 30 percent… Read more »

  • Maximize 340B Program Results

    RxStrategies prides itself on offering intuitive contract pharmacy management through advanced reporting and analytics. Our conservative approach to 340B maximizes program results by ensuring more of the 340B savings remain with Covered Entity (CE) through a simple, all-inclusive fee. Another way our contract pharmacy solution is able to maximize results is through our audit-proven eligibility… Read more »

  • Clinical Insights: November 7, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Lorbrena® (lorlatinib) – New Drug Approval – November 2, 2018 – The Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with… Read more »

  • Clinical Insights: October 10, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval TegsediTM (inotersen) – October 5, 2018 – Akcea Therapeutics, Inc., an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc., announced that the U.S. Food and Drug… Read more »